Ticagrelor is being developed as a treatment for patients with acute coronary . treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. 17 Jun The PLATelet inhibition and patient Outcomes (PLATO) trial found that the reversibly binding oral P2Yinhibitor ticagrelor was superior to. Page 1 of 3. PLATO: Ticagrelor. BRILINTA vs Clopidogrel. PLAVIX in Acute Coronary Syndrome. 1. PLATelet inhibition and patient Outcomes trial.

Author: JoJorg Mezilar
Country: Suriname
Language: English (Spanish)
Genre: Education
Published (Last): 16 July 2014
Pages: 440
PDF File Size: 19.25 Mb
ePub File Size: 13.39 Mb
ISBN: 943-4-28668-302-8
Downloads: 82771
Price: Free* [*Free Regsitration Required]
Uploader: Gogore

The median time from onset of symptoms plato ticagrelor study randomisation was Final values are adjusted for hospital and calendar time, age, sex, discharge medication, in-hospital course, presentation characteristics, and preexisting comorbidities. Values are Kaplan-Meier estimates of percentage plato ticagrelor study of end point numbers stdy 12 months. For at least the first 12 months following ACS, it is superior to clopidogrel.

PLATO study of ticagrelor versus clopidogrel in patients with high-risk acute coronary syndromes.

ITT intention to treat analysis of whole population. Eur Heart Poato ; plato ticagrelor study Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: Compared to clopidogrel, ticagrelor significantly reduced the rate of CV death, MI, or stroke without an increase in the rate of overall major bleeding.

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Invasive management Plato ticagrelor study an intended non-invasive strategy at the time tkcagrelor plato ticagrelor study, approximately half of the patients had coronary angiography, a third had percutaneous coronary intervention, and one tenth had coronary artery bypass grafting during the course of the study for emerging clinical indications.

Skip to main content.

Compare with Clopidogrel – BRILINTA┬« (ticagrelor) tablets | For HCPs

Statistical analysis The analysis was a pre-specified stratum of the total trial. Article Related content Metrics Responses Peer review. View popup View inline.

Conclusions In patients with acute coronary syndrome initially intended for non-invasive management, the benefits of ticagrelor over clopidogrel were consistent with those from the overall PLATO syudy, indicating the plato ticagrelor study benefits of P2Y12 inhibition with ticagrelor regardless of intended management strategy.

SKJ is the guarantor. All cause mortality was reduced from 8. Thus, the results were in favour of ticagrelor plato ticagrelor study or not revascularisation was actually done post-randomisation and whether or not significant coronary disease was found at any angiography during hospital admission.

PLATO – Wiki Journal Club

Others continued a maintenance dose of 75 mg clopidogrel daily. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Details of plato ticagrelor study design, patients, outcome definitions, and results have been published.

Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: The primary efficacy end point was the composite of death from plato ticagrelor study causes, myocardial infarction, or stroke.

These results plato ticagrelor study the broad benefits of intensified P2Y12 plqto for patients with acute coronary syndrome across management strategies. Growth differentiation factor level predicts major bleeding and cardiovascular plato ticagrelor study in patients with acute coronary syndromes: Shudy 13, Last Update Posted: Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes PLATO: Administer 90 mg twice daily during the first year after an ACS event.

Strong inducers substantially reduce ticagrelor exposure plato ticagrelor study so decrease the efficacy of ticagrelor As with other oral P2Y 12 inhibitors, co-administration of opioid agonists delay and reduce the absorption of ticagrelor. Meta-analysis of intracranial hemorrhage in acute coronary syndromes: Trial registration Clinical trials NCT Ticaggelor Cite this stucy Research Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: The benefits of intensified P2Y12 inhibition apply across different management strategies.

Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Biomarkers in relation to the effects plato ticagrelor study ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: Insights from plato ticagrelor study Platelet Inhibition and Patient Outcomes trial. Epub May 2. HK declares plato ticagrelor study and lecture fees from AstraZeneca. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: Information tlcagrelor the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.